HBsAg in sex workers follows those of the general population where rates of HBsAg carriers have dropped from about 3–6% in the early 1980s to 1–2% over the past years. It seems that partial vaccination of the susceptible population along with safer sex practices over the past years have decreased exposure of sex workers to the virus in our region. For reasons that are not entirely clear, most epidemiological research and control and prevention efforts of sexually transmitted HBV has focused mainly on homosexual men. However, in the present study it was shown that exposure of transsexual sex workers to HBV is not significantly more frequent when compared with female sex workers. Thus, the estimated as highly promiscuous sexual activity of transsexuals seems to not substantially increase their viral exposure. It is possible, that increase in the use of condoms due to an awareness of other STDs such as AIDS has lowered the incidence of hepatitis B in these individuals. Additionally, infection rate of sex workers, was not dependent on their age or years of legalised sex work. It is likely, that after their official registration, continuous health education encourage them to take safety precautions and therefore minimize exposure to the virus. In contrast, the practice of illegal sex work, which is usually for a time before registering as a sex worker, seems to contribute more in their HBV infection. It seems that screening sex workers for the presence of markers and vaccinating those who are negative would further restrain their exposure to the virus.

A TSAKRIS
Veneral Diseases Clinic, Ministry of Health, Athens, Greece
K P KYRIKAS
S CHRYSOU
The West Attica General Hospital, Athens, Greece
G PAPOUTSAKIS
Ministry of Health, Athens, Greece

Correspondence to: Dr A Tsakris, Department of Microbiology, Medical School, Aristotle University of Thessaloniki, 54006 Greece.


Genital Chlamydia trachomatis infections in primary care

Ross et al have highlighted the significant proportion of genital Chlamydia trachomatis infections which are diagnosed in practice, and that only a minority of cases (13%) in their district were referred to a genitourinary medicine (GUM) clinic. In the same issue of the BMJ, a postal survey revealed that only 30% of general practitioners in England and Wales would refer a woman with a chlamydial infection to a GUM clinic for contact tracing, follow up, and screening for co-infection. It is a matter of concern that of those GPs who would not refer, only 30% would prescribe an appropriate antibiotic treatment.

We have reviewed all genital chlamydial infections (diagnosed by enzyme linked immunosorbant assay and confirmed by direct immunofluorescence) in specimens received from hospital and community clinic settings by the Public Health Laboratory Service in Sheffield during the first half of 1996. Of the total of 308 cases with confirmed positive tests, 158 presented for initial screening at the GUM clinic. Of those presenting to other services, 37 were detected in obstetrics/gynaecology attenders, 34 in patients attending family planning clinics, 73 in patients attending GP surgeries, and six attenders of other services. By cross referencing patient identifiers from positive samples with the GUM clinic register, we found that 64 (90%) of 71 patients attending gynaecology/family planning clinics (where routine referral to GUM is long established) attended the GUM clinic for management of their infection. This demonstrates that routine GUM involvement in the management of chlamydial infection is both acceptable and achievable in Sheffield.

Moreover, of those patients diagnosed in general practice, 42 (58%) also attended GUM clinics either before or after treatment for further management. Overall, GUM clinics contributed wholly or in part to the management of 268 (87%) of all 308 chlamydia positive patients diagnosed in the city during the study period.

Improved community control of genital chlamydia infections' necessities not only that diagnostic facilities are widely available, but also that there is close collaboration between GUM clinics and other health services to ensure that comprehensive management is provided for all diagnosed cases. In Sheffield, considerable effort has been made to successfully establish these links. In other locations where such collaboration is not routine, we strongly advocate that general practitioners and other services which screen for chlamydial infections are educated to utilise GUM facilities for patient notification procedures. This will also allow improved epidemiological surveillance of this common sexually transmitted disease within a service which is renowned for maintenance of patient confidentiality.

Failure of trimethoprim in the treatment of donovonosis

Antibiotics for the treatment of donovonosis include tetracyclines, chloramphenicol, co-trimoxazole, and cephraxine. Co-trimoxazole has been used with considerable success. In India and South Africa the favoured regimen is two tablets of co-trimoxazole twice daily for at least 10 days, and good compliance and results with this dosage have been reported. However, to date at least four cases of failure of co-trimoxazole in the treatment of donovonosis have been reported.

Doctors in the UK have been urged to use trimethoprim alone rather than co-trimoxazole when there is no clear advantage with the latter. This reflects concern about the serious toxicity associated with sulphonamide use, particularly Stevens-Johnson syndrome, blood dyscrasias, and hepatotoxicity. When first introduced, the combination of sulphonamides and trimethoprim was shown in vitro to be synergistic, but studies have shown trimethoprim to be just as effective as co-trimoxazole in the treatment of chest and urinary tract infections. The use of the combination has not reduced the incidence of resistance to trimethoprim. With the exception of two reports, sulphonamides have not been found to be useful in the treatment of donovonosis, other than as a component of co-trimoxazole; with this in mind, it seems prudent to prescribe trimethoprim instead. We are not aware of any trials of the use of trimethoprim in the treatment of donovonosis. Here we describe failure of trimethoprim in treatment of a case of donovonosis.

Our patient, a Jamaican man, presented with a penile ulcer of 8 weeks' duration (fig). There was no dysuria or urethral discharge. He had visited a family doctor 3 months previously in Jamaica. Initial diagnostic tests were negative for chlamydia, gonorrhoea, and trichomonas. Repeated dark ground microscopy examinations on 3 subsequent days were negative for spirochaetes, and culture for Haemophilus ducreyi was also negative. Our patient was treated initially with trimethoprim, 200 mg twice daily. After 3 weeks there was no improvement in the lesion. After 6 weeks, repeated dark ground and serological tests for treponemal infection were negative, a biopsy was performed, which

Lesion of donovonosis on penis.

Accepted for publication 12 February 1997
Genital Chlamydia trachomatis infections in primary care.

K E Rogstad, D J Kellock, M Horton and G Kudesia

*Genitourin Med* 1997 73: 224
doi: 10.1136/sti.73.3.224

Updated information and services can be found at:
http://sti.bmj.com/content/73/3/224.1.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/